A new study indicates that potassium isotope analysis could facilitate earlier identification of Alzheimer’s disease.
A recent study has opened the door to a promising new method for the early detection of Alzheimer’s disease (AD). Focusing on biomarkers found in blood samples, the study suggests that potassium isotope analysis could become a crucial tool in diagnosing Alzheimer’s before clinical symptoms appear [1]. Published in Metallomics, this pilot study offers a novel application of geochemistry techniques in a medical context, and paves the way for potential advancements in the diagnosis and management of Alzheimer’s.
Longevity.Technology: The importance of early diagnosis in Alzheimer’s cannot be overstated. The most common form of dementia, Alzheimer’s disease accounts for approximately 60-70 percent of all dementia cases, according to the World Health Organization [2]. Early detection is particularly vital because it can delay the onset of severe symptoms, affording patients a greater quality of life, and it also enables patients and their families to plan for the future more effectively and allows clinicians to initiate treatments that may slow disease progression. Additionally, early detection facilitates participation in clinical trials, thereby contributing to the development of new therapies and interventions.
Current methods of diagnosing Alzheimer’s involve a combination of neurological examinations, cognitive assessments and protein analysis of cerebrospinal fluid or blood. However, these methods have limitations, especially in the preclinical stages of the disease. A team led Dr Brandon Mahan from the University of Melbourne, working alongside neuroscientists from the Faculty of Medicine, Dentistry and Health Sciences at The Florey, sought to address these shortcomings by developing a blood test based on inorganic biomarkers – namely, potassium isotopes.
The research, which involved 20 serum samples from the Australian Imaging, Biomarker and Lifestyle study, explored the levels of potassium isotopes in both healthy individuals and Alzheimer’s patients. The key finding was that Alzheimer’s patients exhibited a significantly lower mean ratio of potassium isotopes (δ41K) compared with the control group [1]. The difference, while requiring further validation in larger cohorts, indicates the potential of potassium isotope analysis as a diagnostic tool.
Mahan emphasized the scalability of this technique and its advantages over current methods which make it particularly appealing for long-term clinical applications.
“Our minimally invasive test assesses the relative levels of potassium isotopes in human blood serum and shows potential to diagnose AD before cognitive decline or other disease symptoms become apparent, so action can be taken to reduce the impacts,” he said. “Our test is scalable and – unlike protein-based diagnostics that can break down during storage – it avoids sample stability issues because it assesses an inorganic biomarker [3].”
The mechanism behind the altered potassium isotope ratios in AD patients is linked to potassium dysregulation in the brain. AD is associated with disruptions in potassium transport, particularly involving the Na/K ATPase system, which may lead to a measurable efflux of potassium from the brain into the bloodstream; this process appears to leave a distinct isotopic signature in the blood that could serve as an early biomarker for the disease.
Further mechanistic insights were provided by density functional theory (DFT) calculations, which supported the hypothesis that the isotopic shift observed in AD patients’ serum could be explained by changes in potassium speciation. The study concluded that enhanced levels of hydrated potassium ions in the bloodstream, likely due to a failure in potassium regulation in the brain, contributed to the lighter δ41K values detected in AD patients.
Professor Ashley Bush, a co-author from The Florey, expressed optimism about the potential applications of this technique but cautioned that further research was necessary. “Our blood test successfully identified AD and shows diagnostic power that could rival leading blood tests currently used in clinical diagnosis,” he said. “Significant further work is required to determine the ultimate utility of this promising technique [3].”
While the study’s results are preliminary, they are consistent with other research pointing to the importance of ion transport dysregulation in the early stages of Alzheimer’s disease. Stable potassium isotopes, in particular, may offer a robust biomarker due to their stability during storage and transport – an important consideration for large-scale screening programs. In the future, combining potassium isotope analysis with existing plasma biomarkers, such as amyloid-β and tau proteins, could enhance the diagnostic accuracy and provide a more comprehensive understanding of the disease’s pathology.
The global burden of Alzheimer’s is expected to rise dramatically as populations age, and it is estimated that the number of dementia sufferers will double every 20 years, with the global cost of dementia projected to reach $2.8 trillion by 2030 [4]. Early detection strategies, such as the one explored in this study, will be critical to mitigating both the personal and economic impacts of the disease.
Looking ahead, Mahan and his team plan to expand their research by examining a larger cohort of subjects, which will allow them to assess potential demographic influences such as age, sex and genetic factors. Potassium isotope analysis could eventually play a key role in reducing the global burden of Alzheimer’s disease, and combining potassium isotope measurements with other diagnostic tools could lead to a more holistic and accurate approach to early Alzheimer’s diagnosis.
[1] https://academic.oup.com/metallomics/advance-article/doi/10.1093/mtomcs/mfae038/7746759
[2] https://www.who.int/news-room/fact-sheets/detail/dementia
[3] https://science.unimelb.edu.au/about/news/novel-biomarker-could-lead-to-early-diagnosis-of-alzheimers-disease
[4] https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/
